These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36309184)

  • 1. Activation of the NLRP3 inflammasome by CCl
    Vargas-Pozada EE; Ramos-Tovar E; Rodriguez-Callejas JD; Cardoso-Lezama I; Galindo-Gómez S; Gil-Becerril K; Vásquez-Garzón VR; Arellanes-Robledo J; Tsutsumi V; Villa-Treviño S; Muriel P
    Ann Hepatol; 2023; 28(1):100780. PubMed ID: 36309184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caffeine Inhibits NLRP3 Inflammasome Activation by Downregulating TLR4/MAPK/NF-κB Signaling Pathway in an Experimental NASH Model.
    Vargas-Pozada EE; Ramos-Tovar E; Rodriguez-Callejas JD; Cardoso-Lezama I; Galindo-Gómez S; Talamás-Lara D; Vásquez-Garzón VR; Arellanes-Robledo J; Tsutsumi V; Villa-Treviño S; Muriel P
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benzyl isothiocyanate ameliorates high-fat/cholesterol/cholic acid diet-induced nonalcoholic steatohepatitis through inhibiting cholesterol crystal-activated NLRP3 inflammasome in Kupffer cells.
    Chen HW; Yen CC; Kuo LL; Lo CW; Huang CS; Chen CC; Lii CK
    Toxicol Appl Pharmacol; 2020 Apr; 393():114941. PubMed ID: 32126212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage.
    Huang S; Wu Y; Zhao Z; Wu B; Sun K; Wang H; Qin L; Bai F; Leng Y; Tang W
    Metabolism; 2021 Jul; 120():154797. PubMed ID: 33984334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: a plausible role of adropin.
    Yang W; Liu L; Wei Y; Fang C; Liu S; Zhou F; Li Y; Zhao G; Guo Z; Luo Y; Li L
    Lab Invest; 2021 Mar; 101(3):369-380. PubMed ID: 33268842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
    J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletion of Thioredoxin-interacting protein ameliorates high fat diet-induced non-alcoholic steatohepatitis through modulation of Toll-like receptor 2-NLRP3-inflammasome axis: Histological and immunohistochemical study.
    Mohamed IN; Sarhan NR; Eladl MA; El-Remessy AB; El-Sherbiny M
    Acta Histochem; 2018 Apr; 120(3):242-254. PubMed ID: 29482933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic high-fat diet induces galectin-3 and TLR4 to activate NLRP3 inflammasome in NASH.
    Li H; Cao Z; Wang L; Li J; Cheng X; Tang Y; Xing M; Yao P
    J Nutr Biochem; 2023 Feb; 112():109217. PubMed ID: 36402251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NLRP3 inflammasome activation is required for fibrosis development in NAFLD.
    Wree A; McGeough MD; Peña CA; Schlattjan M; Li H; Inzaugarat ME; Messer K; Canbay A; Hoffman HM; Feldstein AE
    J Mol Med (Berl); 2014 Oct; 92(10):1069-82. PubMed ID: 24861026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-specific Deletion of NLRP3 Inflammasome Identifies Myeloid Cells as Key Drivers of Liver Inflammation and Fibrosis in Murine Steatohepatitis.
    Kaufmann B; Kui L; Reca A; Leszczynska A; Kim AD; Booshehri LM; Wree A; Friess H; Hartmann D; Broderick L; Hoffman HM; Feldstein AE
    Cell Mol Gastroenterol Hepatol; 2022; 14(4):751-767. PubMed ID: 35787975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic deletion or pharmacologic inhibition of the Nlrp3 inflammasome did not ameliorate experimental NASH.
    Ioannou GN; Horn CL; Kothari V; Yeh MM; Shyu I; Lee SP; Savard CE
    J Lipid Res; 2023 Feb; 64(2):100330. PubMed ID: 36641116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development.
    He K; Zhu X; Liu Y; Miao C; Wang T; Li P; Zhao L; Chen Y; Gong J; Cai C; Li J; Li S; Ruan XZ; Gong J
    Oncotarget; 2017 Jun; 8(23):37657-37672. PubMed ID: 28499273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yang-Gan-Jiang-Mei formula alleviates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome through mitophagy.
    Wu Y; Kuang Y; Wu Y; Dai H; Bi R; Hu J; Sun L
    Biotechnol Genet Eng Rev; 2024 Oct; 40(2):1314-1333. PubMed ID: 36960758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicotinic acid attenuates experimental non-alcoholic steatohepatitis by inhibiting the NLRP3 inflammasome/pyroptosis pathway.
    Cardoso-Lezama I; Fuentes-Figueroa MÁ; Ramos-Tovar E; Márquez-Quiroga LV; Ortiz-Fernández A; Vargas-Pozada EE; Arellanes-Robledo J; Tsutsumi V; Muriel P
    Biochem Pharmacol; 2023 Oct; 216():115762. PubMed ID: 37604293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sweroside Prevents Non-Alcoholic Steatohepatitis by Suppressing Activation of the NLRP3 Inflammasome.
    Yang G; Jang JH; Kim SW; Han SH; Ma KH; Jang JK; Kang HC; Cho YY; Lee HS; Lee JY
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Panaxydol extracted from Panax ginseng inhibits NLRP3 inflammasome activation to ameliorate NASH-induced liver injury.
    Kim MY; Jeong B; Lee GS; Jeon H; Yang YM; Yang H; Han YH
    Int Immunopharmacol; 2024 Feb; 128():111565. PubMed ID: 38262161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase.
    Shi W; Xu G; Gao Y; Zhao J; Liu T; Zhao J; Yang H; Wei Z; Li H; Xu AL; Bai Z; Xiao X
    J Transl Med; 2023 Oct; 21(1):700. PubMed ID: 37805545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis.
    Zhang NP; Liu XJ; Xie L; Shen XZ; Wu J
    Lab Invest; 2019 Jun; 99(6):749-763. PubMed ID: 30700851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morroniside delays the progression of non-alcoholic steatohepatitis by promoting AMPK-mediated lipophagy.
    Zhang C; Tong Q; Liu K; Mao T; Song Y; Qu Y; Chen X; Qiu Z
    Phytomedicine; 2024 Jul; 129():155703. PubMed ID: 38723527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis.
    Povero D; Lazic M; McBride C; Ambrus-Aikelin G; Stansfield R; Johnson CD; Santini AM; Pranadinata RF; McGeough MD; Stafford JA; Hoffman HM; Feldstein AE; Veal JM; Bain G
    J Pharmacol Exp Ther; 2023 Aug; 386(2):242-258. PubMed ID: 37308266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.